国盛证券研究所补齐医药团队，张雪、李慧瑶担任医药生物联席负责人

Group 1 - The core viewpoint of the news is the appointment of Zhang Xue and Li Huiyao as co-heads of the pharmaceutical and biotechnology research team at Guosheng Securities, indicating a strategic move to strengthen their research capabilities in the pharmaceutical sector [1] - Zhang Xue has a Master's degree in Public Health from Peking University and possesses a dual background in medicine and finance, with 8 years of experience in pharmaceutical research, previously working at Chuan Cai Securities, Xinda Securities, and Tianfeng Securities [1] - Li Huiyao holds a PhD in Medicine from Sun Yat-sen University and has 6 years of experience in pharmaceutical research, having worked at Xinda Securities and Tianfeng Securities [1] Group 2 - The recruitment of multiple analysts, including two co-heads for the pharmaceutical sector, reflects Guosheng Securities' commitment to expanding its research team and enhancing its analytical capabilities in the healthcare industry [1] - The article also mentions another analyst, who has a Master's degree in Management from Shanghai Jiao Tong University and 4 years of experience in pharmaceutical research, focusing on traditional Chinese medicine, pharmacies, and distribution [8] - Additionally, a research assistant with a Bachelor's degree in Biotechnology from Wuhan University and a Master's in Biomedical Engineering from the National University of Singapore is part of the team, concentrating on innovative drug research and clinical progress [10]